Published: 31. May, 2021
Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports…
Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports last subject dosed ahead of timelines. Primary aim of the trial is to demonstrate drug-exposure following nasal administration of CT001 relative to the IV injection of the approved analgesic drugs
12. May, 2023
First quarter report Q1-2023 Study 0205 is progressing, with last patient expected in Q3...
23. March, 2023
On 23 March 2023 Cessatech A/S announces that the Board of Directors has appointed...
28. February, 2023
Cessatech today publishes its annual report for the fiscal year 2022, which also includes...
Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.